Last reviewed · How we verify
Dosing according residual heparin
This is a dosing protocol that adjusts heparin administration based on residual heparin levels in the patient's blood to maintain therapeutic anticoagulation.
This is a dosing protocol that adjusts heparin administration based on residual heparin levels in the patient's blood to maintain therapeutic anticoagulation. Used for Anticoagulation dosing optimization in patients requiring heparin therapy.
At a glance
| Generic name | Dosing according residual heparin |
|---|---|
| Sponsor | Fundación Clínica Shaio |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Rather than a drug itself, this represents a clinical dosing strategy where heparin doses are individualized by measuring residual (remaining) heparin concentrations and adjusting subsequent doses accordingly. This approach aims to optimize anticoagulation efficacy while minimizing bleeding risk by maintaining heparin levels within a therapeutic window.
Approved indications
- Anticoagulation dosing optimization in patients requiring heparin therapy
Common side effects
- Bleeding
- Thrombosis (if underdosed)
- Heparin-induced thrombocytopenia (HIT)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dosing according residual heparin CI brief — competitive landscape report
- Dosing according residual heparin updates RSS · CI watch RSS
- Fundación Clínica Shaio portfolio CI